MX2022012919A - Anticuerpos anti-flt3 y composiciones. - Google Patents

Anticuerpos anti-flt3 y composiciones.

Info

Publication number
MX2022012919A
MX2022012919A MX2022012919A MX2022012919A MX2022012919A MX 2022012919 A MX2022012919 A MX 2022012919A MX 2022012919 A MX2022012919 A MX 2022012919A MX 2022012919 A MX2022012919 A MX 2022012919A MX 2022012919 A MX2022012919 A MX 2022012919A
Authority
MX
Mexico
Prior art keywords
compositions
flt3 antibodies
flt3
antibodies
patient
Prior art date
Application number
MX2022012919A
Other languages
English (en)
Spanish (es)
Inventor
Mikkel Wandahl Pedersen
Trine Lindsted
Eva Maria Carlsen Melander
Randi Westh Hansen
Matteo Riva
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of MX2022012919A publication Critical patent/MX2022012919A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022012919A 2020-04-14 2021-04-14 Anticuerpos anti-flt3 y composiciones. MX2022012919A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063009578P 2020-04-14 2020-04-14
PCT/EP2021/059646 WO2021209495A1 (en) 2020-04-14 2021-04-14 Anti-flt3 antibodies and compositions

Publications (1)

Publication Number Publication Date
MX2022012919A true MX2022012919A (es) 2022-11-16

Family

ID=75530015

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012919A MX2022012919A (es) 2020-04-14 2021-04-14 Anticuerpos anti-flt3 y composiciones.

Country Status (17)

Country Link
US (2) US12252539B2 (cg-RX-API-DMAC7.html)
EP (1) EP4136114A1 (cg-RX-API-DMAC7.html)
JP (1) JP7679399B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220167331A (cg-RX-API-DMAC7.html)
CN (1) CN115715297A (cg-RX-API-DMAC7.html)
AU (1) AU2021255884A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022020683A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180188A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002833A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022014520A2 (cg-RX-API-DMAC7.html)
IL (1) IL297269A (cg-RX-API-DMAC7.html)
MX (1) MX2022012919A (cg-RX-API-DMAC7.html)
PE (1) PE20230075A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552710A1 (cg-RX-API-DMAC7.html)
TW (1) TWI910146B (cg-RX-API-DMAC7.html)
WO (1) WO2021209495A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202211267B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20230075A1 (es) * 2020-04-14 2023-01-11 Servier Lab Anticuerpos anti-flt3 y composiciones
WO2024108163A2 (en) * 2022-11-18 2024-05-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Molecules that bind to cd135 polypeptides
US20260217851A1 (en) * 2022-12-22 2026-07-30 The Medical College Of Wisconsin, Inc. Compositions that Target CD138 and CD3 and Methods of Making and Using the Same
CN122055383A (zh) * 2023-07-12 2026-05-15 费诺米人工智能公司 抗cthrc1 t细胞衔接体及其使用方法
CN118924724B (zh) * 2024-07-29 2025-11-04 湖南大学 一种用于治疗神经母细胞瘤的药物组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1186301B1 (en) 1993-09-08 2006-08-16 Imclone Systems, Inc. Monoclonal antibodies that recognize flk-2 receptors and the isolation of primitive hematopoietic stem cell populations
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
JP2002522063A (ja) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
WO2002066044A2 (en) 2000-10-24 2002-08-29 Immunex Corporation Method for dendritic cells based immunotherapy of tumors using combination therapy
AR071891A1 (es) 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
ES2573642T3 (es) 2009-12-23 2016-06-09 Synimmune Gmbh Anticuerpos anti-FLT3 y métodos de usar los mismos
KR20240056629A (ko) 2014-09-28 2024-04-30 더 리전트 오브 더 유니버시티 오브 캘리포니아 자극성 및 비자극성 골수성 세포의 조절
TWI829617B (zh) * 2015-07-31 2024-01-21 德商安美基研究(慕尼黑)公司 Flt3及cd3抗體構築體
EP3559038B1 (en) 2016-12-21 2022-12-14 The United States of America as represented by The Secretary Department of Health and Human Services Human monoclonal antibodies specific for flt3 and uses thereof
PE20241587A1 (es) 2017-06-02 2024-08-01 Pfizer Receptores de antigenos quimericos que se dirigen a flt3
JP7234142B2 (ja) 2017-06-02 2023-03-07 ファイザー・インク Flt3に特異的な抗体およびその使用
EP3850010A1 (en) * 2018-09-11 2021-07-21 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Improved anti-flt3 antigen binding proteins
EP3902836B1 (en) * 2018-12-18 2026-03-25 Boehringer Ingelheim IO Canada Inc. Flt3 agonist antibodies and uses thereof
PE20230075A1 (es) * 2020-04-14 2023-01-11 Servier Lab Anticuerpos anti-flt3 y composiciones

Also Published As

Publication number Publication date
EP4136114A1 (en) 2023-02-22
KR20220167331A (ko) 2022-12-20
US12252539B2 (en) 2025-03-18
US20210317216A1 (en) 2021-10-14
JP7679399B2 (ja) 2025-05-19
ZA202211267B (en) 2026-05-27
TW202200620A (zh) 2022-01-01
CA3180188A1 (en) 2021-10-21
WO2021209495A1 (en) 2021-10-21
CL2022002833A1 (es) 2023-06-09
PE20230075A1 (es) 2023-01-11
TWI910146B (zh) 2026-01-01
US20250179195A1 (en) 2025-06-05
CO2022014520A2 (es) 2022-11-08
BR112022020683A2 (pt) 2022-11-29
IL297269A (en) 2022-12-01
CN115715297A (zh) 2023-02-24
AU2021255884A1 (en) 2022-11-17
JP2023522630A (ja) 2023-05-31
PH12022552710A1 (en) 2024-03-25

Similar Documents

Publication Publication Date Title
PH12022552710A1 (en) Anti-flt3 antibodies and compositions
MX2022011676A (es) Proteinas de fusion de il12 con enmascaramiento y metodos para su uso.
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
MX2018014175A (es) Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso.
PH12018502112A1 (en) Anti-tim-3 antibodies and compositions
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
MX370573B (es) Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer.
MX386613B (es) El uso de un péptido timosina alfa y un inhibidor de pd-1 para el tratamiento de cáncer o una metástasis de este en un sujeto.
MY190034A (en) Method of treating cancer associated with a ras mutation
PH12023553123A1 (en) Anti-nkg2a antibodies and compositions
GEP20217317B (en) Combination therapy for the treatment of cancer
MX2024014239A (es) Composiciones que comprenden secuencias de consenso de tert y sus usos en el tratamiento del cancer
EA201890968A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
MX2020011817A (es) Metodos para tratar el linfoma.
PH12022551021A1 (en) Sequential anti-cd19 therapy
MX2020001727A (es) Terapia de combinacion.
MX2019013862A (es) Terapia de combinacion.
TR201811308T4 (tr) Kanser kok hücrelerini azaltan anti-emp2 tedavisi.
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
MX2024002069A (es) Anticuerpos anti-hla-g.
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
MY200803A (en) Mpo inhibitors for use in medicine
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
WO2019168897A3 (en) Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
PH12021551352A1 (en) Anti-periostin antibodies and uses thereof